CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

News Releases

News Releases

CV Sciences, Inc. to Present at 9th Annual Biotech Showcase

LAS VEGAS, NV–(Marketwired – December 22, 2016) – CV Sciences, Inc. (OTCBB: CVSI) (the “Company”), announced today that it will be presenting at the 9th Annual Biotech Showcase to be held January 9-11, 2017 at the Hilton San Francisco Union Square in San Francisco, CA. Event: 9th Annual Biotech Showcase Location: Hilton San Francisco Union … Continue reading CV Sciences, Inc. to Present at 9th Annual Biotech Showcase

CV Sciences, Inc. Highlights Major League Baseball (MLB) Decision to Prohibit All New Players From Using Smokeless Tobacco

LAS VEGAS, NV–(Marketwired – December 20, 2016) – CV Sciences, Inc. (OTCBB: CVSI) (the “Company”, “CV Sciences”, “our” or “we”), today provided comments from its management with regards to the MLB’s recent ban on smokeless chewing tobacco for new players. Beginning this upcoming season, cities that include San Francisco, Boston, and Los Angeles will ban … Continue reading CV Sciences, Inc. Highlights Major League Baseball (MLB) Decision to Prohibit All New Players From Using Smokeless Tobacco

CV Sciences, Inc. Provides Details for Webcast Discussing Its CBD- Based Drug Development Program on November 10, 2016

Company to Discuss Development Efforts and Market Potential of its Proprietary Lead Drug Candidate, CVSI-007 Las Vegas, Nevada, November 3, 2016 – CV Sciences, Inc. (OTCBB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) will hold a webcast on Thursday, November 10, 2016 at 5:00PM Eastern Standard Time to discuss its drug development program and specifically … Continue reading CV Sciences, Inc. Provides Details for Webcast Discussing Its CBD- Based Drug Development Program on November 10, 2016

CV Sciences, Inc. to Host Webcast on its CBD-based Drug Development Program on November 10, 2016

Source: MarketWired Company to Discuss Advances in Program for Development of Therapeutic Products for Cessation of Smokeless Tobacco Use and Addiction — A Market Estimated to Exceed $2 Billion in the U.S. LAS VEGAS, NV–(Marketwired – October 28, 2016) – CV Sciences, Inc. (OTCBB: CVSI) (the “Company”) today announced that it will hold a webcast … Continue reading CV Sciences, Inc. to Host Webcast on its CBD-based Drug Development Program on November 10, 2016

CV Sciences, Inc. Reports Second Quarter 2016 Financial Results

LAS VEGAS, NV–(Marketwired – August 12, 2016) – CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today its financial results for the second quarter and six months ended June 30, 2016. Second Quarter 2016 – Business Highlights Drug Development Program. Following the CanX Acquisition in December 2015, CV Sciences commenced